You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The infectious disease molecular testing firm acquired AdvanDx and went public in the fiscal year. However, full-year revenues fell 23 percent.
The DC Department of Health and District of Columbia Hospital Association are tracking the prevalence of carbapenem-resistant Enterobacteriaceae in healthcare facilities.
Revenues for the quarter rose about 18 percent compared to revenues for the same quarter in 2014.
Twelve hospitals will use the company's assays to screen vulnerable patients for genes from multi-drug resistant organisms.
Revenues for the quarter dropped percent to $375,146 from $1.1 million in the same quarter in 2014.
The acquisition will provide OpGen with FDA-approved and CE-marked tests for use with its MDRO Gene tests and bioinformatics for multidrug-resistant organisms.
The partners will work together to build products based on Fluidigm's Juno and Biomark technology under the five-year deal.
Revenues for the quarter dropped about 55 percent compared to revenues for the same quarter in 2014.
The microbial genetics analysis firm went public today offering 2.85 million units for $17.1 million in gross proceeds.
The company plans to offer 3.75 million shares of its stock at $8 to $10 per share, and anticipates listing on the Nasdaq under ticker symbol "OPGN."
Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.
Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.
Science reports that a Dutch research funding agency is combating a ransomware attack.
In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.